Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Chronic Rhinosinusitis Without Nasal Polyps

Tundra lists 6 Chronic Rhinosinusitis Without Nasal Polyps clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06850805

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.

Gender: All

Ages: 12 Years - 17 Years

Updated: 2026-03-23

14 states

Chronic Rhinosinusitis Without Nasal Polyps
ACTIVE NOT RECRUITING

NCT06691113

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

ACT18421 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo in male and female participants with chronic rhinosinusitis without nasal polyps (CRSsNP) aged 18 years of age and older. Study details include: * The study duration (4-week screening, 24--week intervention, 20--week safety followup) will be 48 weeks. * The intervention duration will be 24 weeks. * The number of visits will be 7 site visits and 8 phone/remote visits.

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-12

25 states

Chronic Rhinosinusitis Without Nasal Polyps
RECRUITING

NCT07184684

Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS).

Chronic rhinosinusitis (CRS) is a disease associated with impaired quality of life and substantial societal costs. Much is still uncertain regarding the underlying etiology of the disease. Current treatment protocols are based on observed effects rather than a mechanistic understanding of the disease and thus patients often report unsatisfactory symptom reduction despite treatment with maximal medical therapy and even surgery. CRS is subgrouped phenotypically based on whether or not polyps are observed. Recently an endotypical differentiation reflecting the underlying inflammatory profile has been recommended as well, especially for research. Increasing interest in the role of the commensal microbiome inflammatory diseases has followed a growing understanding of its profound impact on the human immune system. Current research indicates that instability and dysfunction of the microbiome is linked to inflammatory disease rather than compositional differences. Previous research has shown that microbiome transplants are effective in restoring the commensal microbiome and reducing inflammation in gastrointestinal disease and in a previous pilot study the investigators showed that sinonasal microbiome transplants are feasible and were associated with reduced symptoms in chronic rhinosinusitis without nasal polyps (CRSsNP). This study will examine if the positive effect on patients symptoms observed in a previous pilot study are sustained in a placebo controlled, blinded study. In addition to this the study will also examine any differences in microbiome structure, stability, and function between patients with CRS and healthy donors as well as any correlation to disease phenotype or inflammatory endotype.

Gender: All

Ages: 18 Years - Any

Updated: 2025-09-22

Chronic Rhinosinusitis Without Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
RECRUITING

NCT06398873

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

The investigators aim to investigate two major so far unresolved topics in CRSwNP research: (1) Thorough functional and molecular characterisation of barrier function in patients suffering from CRSsNP and CRSwNP and (2) effect of dupilumab treatment on barrier function in polyp patients. This will be achieved in patient-derived samples by employing measurement of barrier function in primary cell cultures in combination with a mass cytometry based imaging approach, transcriptomic analysis as well as cytokine and microbiome data of individual patients.

Gender: All

Ages: 18 Years - 99 Years

Updated: 2025-05-07

1 state

Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis Without Nasal Polyps
RECRUITING

NCT06118554

3D Printing to Improve Nasal Irrigation Outcome

Three-dimensional (3D) printing has been an emerging technology with uses in a wide array of fields. This research aims to use 3D printing as a tool to provide personalized education to maximize treatment efficacy based on the patient's individual anatomy. With increased irrigation to the sinuses, we hypothesize there will be improved patient satisfaction and higher quality of life. The outcomes of this research could lead to a new option for patients who live with chronic rhinosinusitis are not candidates for surgery or are interested in less invasive options. The 3D printed nasal replica is not something that would be implanted, rather it is a hand-held device used specifically for participants to better understand their nasal anatomy.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-03-21

1 state

Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis Without Nasal Polyps
RECRUITING

NCT05642806

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Gender: All

Ages: 19 Years - Any

Updated: 2024-04-17

1 state

Chronic Rhinosinusitis With Nasal Polyps
Asthma
Chronic Rhinosinusitis Without Nasal Polyps